COMPARATIVE STUDY OF EFFICACY AND SAFETY OF AZITHROMYCIN ALONE AND IN COMBINATION WITH PROBIOTIC IN THE TREATMENT OF IMPETIGO IN CHILDREN
DOI:
https://doi.org/10.22159/ijcpr.2017v9i6.23429Keywords:
Impetigo, Azithromycin, Probiotic, Staphylococcus aureus, Streptococcus pyogenesAbstract
Objective: Impetigo is a superficial infection of the skin that involves only the epidermis. It affects mostly children, usually on exposed areas of the body (eg. The face and the legs). Staphylococcus aureus is the most important causative organism. Streptococcus pyogenes (i.e.) group A beta-hemolytic streptococcus) causes fewer cases, either alone or in combination with S. aureus. The objective of this study is to find out the efficacy and safety of azithromycin alone and in combination with probiotic among children suffering from impetigo.
Methods: This prospective, randomized, single-blinded interventional study was conducted for a period of 6 mo in pediatric OPD and dermatology OPD in Rajah Muthiah Medical College and Hospital. A total of 100 patients, randomly divided into two groups with 50 patients in each group. Group, I patients treated with Azithromycin 10 mg/kg/d for 5 d. Group II patients treated with Azithromycin 10 mg/kg/d for 5 d with probiotic (50 million spores of Lactobacillus sporegens, Streptococcus faecalis 30 million spores, clostridium butyricum 2 million spores, Bacillus mesentericus 1 million spores) twice daily for 5ds.
Results: Reduction in a number of lesions and wound area, clinical response were highly significant in Azithromycin with the probiotic-treated group.
Conclusion: In this study, probiotic bacteria may counteract the inflammatory process beyond the intestinal milieu. The results of this study indicate that Azithromycin with probiotic is effective in the treatment of impetigo.Downloads
References
Mandell, Douglas, Bennett’s. S pyogenic is found in only 20% of cases, in association with S. aureus. Principal Practice Infectious Disease 2010;195:2565-6.
George Hudson Findlay. Several ‘Species’ of impetigo was recognized by Thomas Bateman. Dermatol Bacterial Infection 1985;1:43-4.
Brown J, Shriner DL, Schwartz RA, Janniger CK. Impetigo: an update. Int J Dermatol 2003;42:251-5.
Sladden MJ, Johnston GA. Common skin infections in children. Br Med J 2004;329:95-9.
Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A):73-82.
Salminen S, Bouley C, Boutron–Ruault MC. Functional and science and gastrointestinal physiology and function. Br J Nutr 1998;80:S147-71.
Isolauri E, Arvola T, Sutas E, Moilanen, Salminen S. Probiotic may counteract inflammatory response beyond the intestinal milieu. Clin Exp Allergy 2000;30:1604-10.
George A, Rubin G. A systematic review and meta-analysis of treatments of impetigo. Br J Gen Pract 2003;53:480-7.
Chopra A, Puri R, Mital RR, Kantha S, Bhatia R. A clinical and bacteriological study of pyodermas. Indian J Dermatol Venereol Leprol 1994;60:200-2.
George A, Rubin G. A systematic review and meta analysis of treatments for impetigo. Br J Gen Pract 2003;53:480-7.
Mudd SS, Findlay JS. The cutaneous manifestations and common mimickers of physical child abuse. J Pediatr Health Care 2004;18:123-9.
Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotic on atopic dermatitis: a randomized controlled trials. Arch Dis Child 2005;90:892-7.
Shane AL, Cabana MD, Very S, Merenstein D, Hummelen R, Ellis CL, et al. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. Gut Microbes 2010;1:243-53.
Romagnani S, Maggi E, Parronchi P, Macchia D, Piccinni MP, Ricci M. Increased numbers of Th2-like CD4+T cells in target organs and in the allergen-specific repertoire of allergic patients. possible role of IL-4 produced by non-T cells. Int Arch Allergy Appl Immunol 1991;94:133-6.
Published
How to Cite
Issue
Section
